Axsome Therapeutics Stock Forecast

Stock Price Forecast

According to 21 analysts polled by S&P Global, Axsome Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $276.47. The average 1-year stock price forecast is 9.64% higher than the current stock price, while the lowest is $200 (-20.69%) and the highest is $380 (+50.70%).

Price Target: $276.47 (+9.64%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$200	$276.47	$272	$380
Change	-20.69%	+9.64%	+7.87%	+50.70%

Analyst Ratings

The average analyst rating for Axsome Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	16	17	17	17	17	17
Buy	3	3	3	3	3	3
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	20	21	21	21	21	21

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Joseph Thome TD Cowen	TD Cowen	Buy Reiterates $275 → $300	Buy	Reiterates	$275 → $300	+18.97%	Jun 17, 2026
David Amsellem Piper Sandler	Piper Sandler	Buy Reiterates $258	Buy	Reiterates	$258	+2.32%	Jun 17, 2026
Benjamin Burnett Wells Fargo	Wells Fargo	Buy Maintains $255	Buy	Maintains	$255	+1.13%	Jun 11, 2026
Graig Suvannavejh Mizuho Securities	Mizuho Securities	Buy Reiterates $310	Buy	Reiterates	$310	+22.94%	Jun 4, 2026
Ram Selvaraju H.C. Wainwright	H.C. Wainwright	Buy Reiterates $290	Buy	Reiterates	$290	+15.01%	Jun 4, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

985.50M

from 638.50M

54.35%

from 638.50M

Revenue Next Year

1.60B

from 985.50M

62.10%

from 985.50M

EPS This Year

-1.71

from -3.47

EPS Next Year

5.89

from -1.71

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	50.04M	270.60M	385.69M	638.50M	985.50M
Revenue Growth	-	-	440.80%	42.53%	65.55%	54.35%
Gross Profit	-	45.94M	244.54M	352.39M	591.02M	908.21M
Gross Margin	-	91.81%	90.37%	91.37%	92.56%	92.16%
Operating Income	-124.71M	-175.40M	-182.91M	-252.44M	-169.24M	-98.57M
Net Income	-130.40M	-187.13M	-239.24M	-287.22M	-183.17M	-100.31M
EPS	-	-	-	-	-3.47	-1.71
Free Cash Flow	-59.52M	-43.82M	-87.21M	-38.10M	-29.42M	-60.42M
No. Analysts	-	-	-	-	-	21

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	1.1B
Avg	985.5M
Low	867.6M

Revenue Growth

Revenue Growth	2026	2027	2028
High	75.3%
Avg	54.3%
Low	35.9%

EPS Forecast

EPS	2026	2027	2028
High	1.30
Avg	-1.71
Low	-3.35

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-